论文部分内容阅读
Background: The first objective of RTOG 0617 was to compare the overall survival(OS)of patients(pts)treated with standard-dose(SD)(60Gy)versus high-dose(HD)(74Gy)radiotherapy with concurrent chemotherapy(CT).Methods: This Phase Ⅲ Intergroup trial randomized 464 pts with Stage Ⅲ NSCLC to the SD(60Gy)vs.HD(74Gy)arms prior to closure of the HD arm.Concurrent CT included weekly paclitaxel(45 mg/m2)and carboplatin(AUC=2).Pts randomized to cetuximab received a 400 mg/m2 loading dose on Day 1 followed by weekly doses of 250 mg/m2.All pts were to receive consolidation CT.We are reporting the final results on radiation dose.Results: 464 pts were accrued prior to closure of the HD arm in 6/11,of which 419 were eligible for analysis.Median follow up was 17.2 months.There were 2 and 10 grade 5 treatment-related adverse events(AEs)on the SD and HD arms,respectively.Grade 3+AEs were 74.2%and 78.2%on SD and HD arms,respectively(p=0.34).The median survival times and 18-month OS rates for the SD and HD arms were 28.7 vs 19.5 months,and 66.9%vs 53.9%respectively(p=0.0007).The primary cause of death was lung cancer(72.2%vs 73.5%)(p=0.84).Local failure rates at 18 months were 25.1%vs 34.3%for SD and HD patients,respectively(p=0.03).Local-regional and distant failures at 18 months were 35.3%vs 44%(p=0.04)and 42.4%vs 47.8%(p=0.16)for SD and HD arms,respectively.Factors predictive of less favorable OS on multivariate analysis were higher radiation dose,higher esophagitis/dysphagia grade,greater gross tumor volume,and heart volume >5 Gy.Conclusions: In this setting of chemoradiation for locally-advanced Stage Ⅲ NSCLC,60 Gy is superior to 74 Gy in terms of OS and local-regional control.The effect of the anti-EGFR antibody(cetuximab)awaits further follow up.This project was supported by RTOG grant U10 CA21661,CCOP grant U10 CA37422,and ATC U24 CA 81647 from the National Cancer Institute(NCI)and Eli Lilly and Company.